As the figure shows, the SLC2A10 expression level correlates with poorer prognosis and high immune infiltrates in colon adenocarcinoma (COAD), kidney renal clear cell carcinoma (KIRC), lower grade glioma (LGG) and rectum adenocarcinoma (READ) (Fig. 5A, C, E, I). Here, SLC2A10 is linked to glioma.